Pradaxa Linked To Heart Attack and Bleeding and FDA Undertakes Safety Review

 Pradaxa® is oral anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in some cases it offers an alternative to warfarin as the preferred orally administered anticoagulant ("blood thinner") since it does not require frequent blood tests for international normalized ratio (INR) monitoring while offering similar results in terms of efficacy.  It was developed by Boehringer Ingelheim.

Pradaxa® was approved by the FDA in October 2010 for stroke prevention in patients with atrial fibrillation. It is the first of a new crop of blood clot preventers meant to replace warfarin -- a longtime oral treatment that carries serious bleeding risks and requires routine blood monitoring and stringent dietary restrictions.

On Dec. 7, 2011, the U.S. Food and Drug Administration (FDA) announced that it had began a formal investigation into the 260 reports of fatal Pradaxa® injuries that occurred from March 2008 to October 2011.

In March 2012, Pradaxa® was linked by the Journal of Neurosurgey to the death of an elderly man who suffered a massive brain hemorrhage after a fall.  It is though that the man hemorrgaed to death becausePraxada prevented blood from clotting.

If you or someone you love has been treated with the anticoagulant medication Pradaxa® (dabigatran) and has suffered a serious side effect such as a heart attack or internal bleeding, a Pradaxa® injury lawsuit may be right for you.  To find out if you qualify to seek compensation for your injuries, please contact us immediately.